Adaptive Biotechnologies Corporation ADPT shares are trading higher Tuesday despite a lack of company-specific news. Here's a look at what's going on:
What To Know:
Adaptive Biotechnologies shares spiked just before the market close on Monday and are up Tuesday on heavy trading volume.
According to data from Benzinga Pro, more than 2.64 million shares have already been traded in the session, compared to the stock's 100-day average of 1.179 million shares.
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system to facilitate the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is authorized by the FDA.
According to data from Benzinga Pro, 9.24% of available ADPT shares are being sold short, and the ticker is listed as one of the top trending on Yahoo! Finance.
Related News: What's Going On With T2 Biosystems Stock Today?
ADPT Price Action: According to Benzinga Pro, ADPT shares are up more than 13% at $5.75 at the time of publication.
Image: Gustavo Rezende from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
